ArticleEvidence-based complementary and alternative medicine : eCAM2022
Naringin Regulates Microglia BV-2 Activation and Inflammation via the JAK/STAT3 Pathway.
Article in Evidence-based complementary and alternative medicine : eCAM, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Therapeutic potential and mechanisms of flavonoids from Citrus grandis 'Tomentosa' in metabolic dysfunction-associated steatotic liver disease: a focus on immune-inflammatory signaling pathways.Frontiers in pharmacology · 2026Pooled it
- KI17: A Bioinspired Peptide Derived fromMolecules (Basel, Switzerland) · 2026Article
- Review
- Naringin alleviates periodontitis via direct AMPK/Nrf2 activation and NLRP3 inhibition, amplified by gut microbiota/Arg-Gln modulation.NPJ biofilms and microbiomes · 2026Article
- Pharmacology-Driven Dissection of Core Component Sets of Xuefu Zhuyu Decoction in Blood Stasis-Related Cardiovascular Diseases.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Network Pharmacological Prediction and Experimental Analyses Reveal That Naringin Alleviates Osteoarthritis Progression by Targeting MMP13.Physiological research · 2026Article
- KANK4 Regulates CXCL16 Glycosylation Through TMEM260 to Modulate Microglial Activation in Sepsis-associated Encephalopathy.Inflammation · 2026Article
- Therapeutic potential of natural arginase modulators: mechanisms, challenges, and future directions.Frontiers in pharmacology · 2025Review
- Plant-derived polyphenolic compounds for managing schizophrenia: mechanisms and therapeutic potential.Frontiers in pharmacology · 2025Review
- Regulatory mechanism and therapeutic potentials of naringin against inflammatory disorders.Heliyon · 2024Review
- Potential Beneficial Effects of Naringin and Naringenin on Long COVID-A Review of the Literature.Microorganisms · 2024Review
- Pre-clinical Evidence-based Neuroprotective Potential of Naringin against Alzheimer's Disease-like Pathology: A Comprehensive Review.Current pharmaceutical biotechnology · 2024Review
- Naringin inhibits P2X4 receptor expression on satellite glial cells in the neonatal rat dorsal root ganglion.Journal of applied biomedicine · 2023Article
- Etanercept alleviates psoriasis by reducing the Th17/Treg ratio and promoting M2 polarization of macrophages.Immunity, inflammation and disease · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Microglial BV-2 cells are activated in the brain following insomnia. Naringin (NAR) is a polymethoxylated flavonoid that is also commonly found in citrus fruits and is known for its antioxidant potential. However, the effect of NAR on microglial cells has rarely been studied in the brain of an organism after insomnia. This study aimed to investigate the effects and potential mechanisms of action of NAR on microglial cell activation and inflammation. Methods: BV-2 cells were obtained from the China Center for Type Culture Collection and randomly divided into five treatment groups: control, model, NAR (10 Results: Compared with the control group, cell migration, cell viability, and the expression of IL-1 Conclusion: NAR treatment inhibited the proliferation, migration, and inflammation of BV-2 cells as well as the activation of microglia to the M1 phenotype. Conversely, NAR treatment promoted the activation of microglia to the M2 phenotype and enhanced the phagocytic function of BV-2 cells by regulating the activity of the JAK/STAT3 pathway.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.